Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
News|Articles|September 15, 2023
BENEO galenIQ™
Author(s)Beneo
BENEO produces galenIQ™, a water-soluble filler and binder. galenIQ™ has a sweetness and taste profile similar to sucrose, therefore it’s used to improve palatability of bitter-tasting active pharmaceutical ingredients and plant extracts.
About galenIQ™
BENEO GmbH is part of the Südzucker Group and a member of the International Pharmaceutical Excipients Council (IPEC). BENEO produces galenIQ™ (Isomalt Ph. Eur., BP, USP-NF, JP), which is a water-soluble filler and binder. Derived from sucrose, galenIQ™ has a sweetness and taste profile that is very similar to sucrose and therefore galenIQ™ is frequently used to improve the palatability of bitter-tasting active pharmaceutical ingredients (APIs) and plant extracts.
galenIQ™ is available in different median particle sizes, morphologies and solubilities, which makes it the optimal choice for the formulation of a broad variety of dosage forms, such as chewable tablets, compressed lozenges, oro-dispersible mini-tablets, effervescents, and cough syrups.
BENEO is a division of the Südzucker Group, that employs more than 1000 people and has production units in Belgium, Chile, Germany and Italy.
For further information please contact:
Dr. Maj-Britt Cepok, Head of Business Development Pharma
Maximilianstraße 10, 68165 Mannheim, Germany
Phone: +49 621 421 150
Fax: +49 621 421 160
Email:
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.